Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
STEVEN Terry ROSEN · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · 2022 · $250,000 — Project Summary/Abstract Novel targeted therapies for HPV-associated Non-AIDS-defining cancers (Biospecimens/Biocohort) The incidents of non-AIDS-defining cancers (NADC) are increasing in HIV-infected individuals (HIVIIs), urging the development of therapeutic interventions. Many HIV-associated canc…
Zheng-Yi Chen · MASSACHUSETTS EYE AND EAR INFIRMARY · 2022 · $505,567 — Abstract Genetic blindness is prevalent with limited treatment options. Despite tremendous progress in the development of editing technology as potential therapy for blindness, the ability to deliver the editing complex into the retina for efficient editing remains a major challenge. The current pre…
Prabhani Atukorale · UNIVERSITY OF MASSACHUSETTS AMHERST · 2022 · $194,308 — PROJECT SUMMARY Despite their transformative promise, traditional cancer vaccines have had poor clinical responses since vaccine-specific systemic T cells often cannot traffic to immunosuppressed “cold” tumors. Traditional vaccines generate only a lymph node-derived augmentation or “prime” of system…
Andre Elias Nel · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2022 · $529,313 — The use of nano-enabled chemotherapy to trigger an immune response to pancreatic ductal adenocarcinoma (PDAC) introduces a novel approach for overcoming robust barriers to immunotherapy, including poor immunogenicity, low neoantigen burden, stromal interference (“T-cell exclusion”), overexpression o…
Jinjun Shi · BRIGHAM AND WOMEN'S HOSPITAL · 2022 · $687,224 — ABSTRACT With the ability to silence individual genes and to drug the ‘undruggable’, RNA interference (RNAi) therapy has recently shown clinical success by delivering small interfering RNA (siRNA) to the liver for genetic diseases. However, new delivery strategies will be needed to expand the target…
Jonathan Henry Shannahan · PURDUE UNIVERSITY · 2022 · $337,723 — Project Summary / Abstract Individuals with metabolic syndrome (MetS) compose a significant and growing proportion of our U.S. and global population (> 25%). It has been established that the presence of chronic diseases, such as MetS, enhances and prolongs environmental exposure-induced inflammation…
Karen N. Allen · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2022 · $185,103 — Complex glycoconjugates play a pivotal role in bacterial survival, colonization and virulence and contribute to the interactions between symbiotic and pathogenic bacteria and their human hosts. An important mechanism for the assembly of these structures is initiated on the cytoplasmic face of cell m…
Jayanth Panyam · TEMPLE UNIV OF THE COMMONWEALTH · 2022 · $352,261 — Agonists of toll like receptors (TLRs) are promising anticancer vaccine adjuvants because of their ability to induce proinflammatory cytokines necessary to generate a robust immune response. However, currently available TLR agonists suffer from a number of limitations including self-regulatory immun…
Gretchen Mahler · STATE UNIVERSITY OF NY,BINGHAMTON · 2022 · $302,964 — PROJECT SUMMARY Nanomaterials are increasingly used in consumer products, processed food, and food packaging, and few studies have determined the consequences of nanoparticle ingestion. The ultimate goal of this work is to determine if and how ingested metal oxide nanoparticles alter microorganism p…
Gregory A. Newby · BROAD INSTITUTE, INC. · 2022 · $166,860 — PROJECT SUMMARY Genetic diseases impact over 1 in 50 newborns worldwide and yet there are no approved therapies capable of correcting the underlying genetic defects. As a result, most patients continue to suffer throughout their life and require frequent interventions to ameliorate symptoms. I aim …
Karen N. Allen · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2022 · $437,559 — Complex glycoconjugates play a pivotal role in bacterial survival, colonization and virulence and contribute to the interactions between symbiotic and pathogenic bacteria and their human hosts. An important mechanism for the assembly of these structures is initiated on the cytoplasmic face of cell m…
Howard E Gendelman · UNIVERSITY OF NEBRASKA MEDICAL CENTER · 2022 · $690,750 — ABSTRACT Mononuclear phagocytes (MP; monocytes, macrophages, dendritic cells. and microglia) serve as human immunodeficiency virus type one (HIV-1) reservoirs, sites of viral persistence and latency, and inducers of end- organ disease. All are commonly linked to HIV-1 pathobiology. However, the key …
JENNIFER A DOUDNA · UNIVERSITY OF CALIFORNIA BERKELEY · 2022 · $1,257,377 — PROJECT SUMMARY / ABSTRACT CRISPR-Cas9 has demonstrated incredible potential to provide clinical benefit, but the challenge of delivery currently hinders therapeutic use of genome editing in vivo. Use of viral vectors and lipid nanoparticles has established the viability of in vivo genome editing, b…
James Dahlman · EMORY UNIVERSITY · 2022 · $377,924 — Project Summary Scientists can create thousands of chemically distinct nanoparticles using a growing number of high throughput chemistries, but it is still difficult to test more than a few nanoparticles in vivo. The goal of this work is to substantially improve how lipid nanoparticles (LNPs) delive…
Aleksandra Elzbieta Sikora · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · 2022 · $217,467 — ABSTRACT Neisseria gonorrhoeae (Ng) is a human-specific pathogen and the etiological agent of gonorrhea, a sexually transmitted infection with a significant global health burden of ~78 million new cases annually. While often asymptomatic, untreated gonorrhea can lead to pelvic inflammatory disease, …
michele k evans · NATIONAL INSTITUTE ON AGING · 2022 · $575,495 — We characterized EV attributes across selected age groups of participants from the population based, longitudinal study, Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) in LEPS. We analyzed circulating plasma EVs from the HANDLS study using both a cross-sectional and longit…
Nathan Claude Gianneschi · NORTHWESTERN UNIVERSITY AT CHICAGO · 2022 · $319,697 — Project Summary The Polymeric Materials Synthesis and Characterizations Core will formulate, synthesize, and characterize lead candidates for the mitigation of mustards and provide support and chemical expertise to other cores and projects. The Core will be co-directed by Drs. Nathan Gianneschi (Dep…
Colby Shad Thaxton · NORTHWESTERN UNIVERSITY AT CHICAGO · 2022 · $275,232 — SUMMARY The overall goal of the Lipid-Based Self-Assembled Materials and Characterization Core (LBSAMCC) is to synthesize, characterize, and deliver highly novel therapeutics for ameliorating the devastating effects of nitrogen and sulfur mustards to the eye (Project 1) and skin (Project 2). High-de…
Irina A. Kirpich · UNIVERSITY OF LOUISVILLE · 2022 · $264,780 — Alcoholic liver disease (ALD) is a major and increasing health problem in the US (especially in Kentucky) and worldwide. In spite of the magnitude of this problem, there is no FDA-approved therapy for any stage of ALD. In addition, the mechanisms and regulators of the disease progression and severit…
Cynthia Arbeeny · MITOTHERAPEUTIX, LLC · 2022 · $860,261 — Abstract The goal of this SBIR fast-track application is to carry out a number of IND enabling studies on our siRNA drug candidate, which is designed to treat non-alcohol steatohepatitis (NASH). NASH is a form of non-alcohol fatty liver disease (NAFLD) and results from a pathological accumulation of…